GSA Capital Partners LLP Has $301,000 Stock Holdings in Personalis, Inc. $PSNL

GSA Capital Partners LLP decreased its position in Personalis, Inc. (NASDAQ:PSNL) by 62.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 46,193 shares of the company’s stock after selling 77,921 shares during the period. GSA Capital Partners LLP owned 0.05% of Personalis worth $301,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Aberdeen Group plc boosted its stake in Personalis by 35.7% in the third quarter. Aberdeen Group plc now owns 2,387,947 shares of the company’s stock valued at $15,569,000 after acquiring an additional 628,450 shares during the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its stake in shares of Personalis by 99.3% in the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 185,036 shares of the company’s stock valued at $1,206,000 after purchasing an additional 92,195 shares during the period. AIGH Capital Management LLC boosted its position in shares of Personalis by 4.5% in the 3rd quarter. AIGH Capital Management LLC now owns 3,892,101 shares of the company’s stock worth $25,376,000 after purchasing an additional 168,143 shares during the last quarter. Howland Capital Management LLC boosted its position in shares of Personalis by 15.9% in the 3rd quarter. Howland Capital Management LLC now owns 330,673 shares of the company’s stock worth $2,156,000 after purchasing an additional 45,365 shares during the last quarter. Finally, Farther Finance Advisors LLC acquired a new stake in shares of Personalis during the third quarter worth $66,000. 61.91% of the stock is currently owned by institutional investors and hedge funds.

More Personalis News

Here are the key news stories impacting Personalis this week:

• Positive Sentiment: Analyst price-target upgrade — Needham raised its PSNL target from $10 to $12 and reiterated a “buy” rating, implying meaningful upside from the current price and signaling increased analyst confidence. Benzinga
• Positive Sentiment: Operational growth target — Management outlined a plan targeting ~170% clinical test-volume growth for 2026 and highlighted acceleration from reimbursement and its MRD (minimal residual disease) strategy, which, if realized, would drive revenue and margin scaling. Seeking Alpha: Clinical Test Volume Growth
• Positive Sentiment: Q4 outperformance vs. EPS estimates — Personalis reported a $0.26 loss per share, beating consensus by $0.05, and delivered revenue roughly in line to slightly above expectations, which supports the near-term stock uplift. Press Release / Q4 Results
• Neutral Sentiment: Earnings call and transcript available — Management commentary and the full Q4 2025 call transcript provide more color on reimbursement progress, MRD commercialization cadence and margin plans; these details will determine whether the growth targets are credible. Yahoo Finance: Q4 Earnings Call Transcript
• Neutral Sentiment: Media coverage / snapshot pieces summarize results and strategy but add little new detail beyond the company release and call. SeattlePI: Q4 Snapshot
• Negative Sentiment: FY2026 revenue guidance set below street expectations — Personalis guided to roughly $78–$80M for FY2026 versus a consensus near $81M, introducing downside risk to near-term estimates and valuation. Yahoo Finance: Full Year Results & Guidance
• Negative Sentiment: Elevated short interest and persistent losses — Short interest rose ~21% in February to ~12.5% of float (an 8.6-day ratio), while the company remains unprofitable with negative margins and ROE, increasing volatility and downside risk if execution slips. MarketBeat: Short Interest & Stock Data
• Negative Sentiment: Conflicting coverage on revenue beat/miss — Some outlets flagged a revenue miss while company/other reports show a slight revenue beat; this mixed narrative can amplify intraday moves as investors parse which data source is authoritative. Zacks: Q4 Loss / Revenue Comment

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Needham & Company LLC raised their target price on Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Friday. Morgan Stanley increased their price target on shares of Personalis from $9.00 to $11.00 and gave the company an “equal weight” rating in a research report on Monday, December 1st. HC Wainwright lifted their price objective on shares of Personalis from $8.50 to $10.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Lake Street Capital restated a “buy” rating and set a $11.00 price objective on shares of Personalis in a report on Wednesday, November 5th. Finally, BTIG Research increased their target price on shares of Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Wednesday, February 11th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $11.14.

Personalis Stock Up 0.3%

Personalis stock opened at $9.06 on Friday. The company has a 50 day moving average of $8.83 and a 200-day moving average of $7.96. Personalis, Inc. has a twelve month low of $2.83 and a twelve month high of $11.50. The stock has a market capitalization of $804.53 million, a PE ratio of -9.96 and a beta of 1.98.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.05. The business had revenue of $17.35 million for the quarter, compared to analysts’ expectations of $17.12 million. Personalis had a negative net margin of 116.69% and a negative return on equity of 42.81%. Equities analysts anticipate that Personalis, Inc. will post -1.4 EPS for the current fiscal year.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.